Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Medical Use and Treatment Costs of Hepatocellular Carcinoma Patients Using National Patient Sample Data

환자표본자료를 이용한 간세포암종 환자의 의료이용 특성 및 치료별 의료비용 분석

  • 오병찬 (성균관대학교 약학대학) ;
  • 조정연 (성균관대학교 약학대학) ;
  • 권순홍 (성균관대학교 약학대학) ;
  • 이의경 (성균관대학교 약학대학) ;
  • 김혜린 (삼육대학교 약학대학)
  • Received : 2021.04.10
  • Accepted : 2021.06.21
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: With increasing economic evaluation studies on the treatment of or screening tools for liver diseases that cause hepatocellular carcinoma (HCC), interest in the analysis of the medical utilization and costs of HCC treatment is increasing. Therefore, we aimed to estimate the medical utilization and costs of HCC patients, and calculate the cost of main procedures for HCC treatment, including liver transplant (LT), hepatic resection (HR), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). Methods: We analyzed claim data from January to December 2018 from the Health Insurance and Review and Assessment Service-National Patient Sample (HIRA-NPS-2018) dataset, including data of patients diagnosed with HCC (Korean Standard Classification of Diseases code C22.0) who had at least one inpatient claim for HCC. Results: A total of 715 HCC patients were identified. In 2018, the yearly average medical cost per HCC patient was ₩18,460K (thousand), of which ₩14,870K was attributed to HCC. Among the total medical costs of HCC patients, the inpatient cost accounted for the largest portion of both the total medical and HCC-related costs. The major procedures of HCC treatment occurred most frequently in the order of TACE, RFA, HR, and LT. The average medical cost per treatment episode was the highest for LT (₩87,280K), followed by HR (₩10,026K), TACE (₩4,047K), and RFA (₩2,927K). Conclusion: By identifying the medical costs of HCC patients and the costs of the main procedures of HCC treatment, our results provide basic information that could be utilized for cost estimation in liver disease-related economic evaluation studies.

Keywords

Acknowledgement

본 연구는 보건복지부 보건의료연구개발사업의 지원에 의하여 이루어졌습니다(과제고유번호: HC20C0062).

References

  1. Korean Statistical Information Service. Cause of Death Statistics. Available from https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B34E01&conn_path=I2. Accessed Nov 15, 2020.
  2. Korean Liver Cancer Association (KLCA). 2018 Korean liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20(7):1042-1113. https://doi.org/10.3348/kjr.2019.0140
  3. Fitzmaurice C, Abate D, Abbasi N, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol 2019;5(12):1749-68. https://doi.org/10.1001/jamaoncol.2019.2996
  4. The Korean Association for the Study of the Liver. White Paper on Liver Diseases in Korea. Available from https://www.kasl.org/bbs/index.html?code=ency&page=1&number=55&mode=view. Accessed February 22, 2021.
  5. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-43. https://doi.org/10.1016/j.jhep.2011.12.001
  6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301-14. https://doi.org/10.1016/S0140-6736(18)30010-2
  7. Khalaf N, Ying J, Mittal S, et al. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15(2):273-81. https://doi.org/10.1016/j.cgh.2016.07.033
  8. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6(12):1418-24. https://doi.org/10.1016/j.cgh.2008.08.005
  9. Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology 2017;65(4):1237-48. https://doi.org/10.1002/hep.28961
  10. Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol 2017;8(6):e101. https://doi.org/10.1038/ctg.2017.26
  11. Kondili LA, Romano F, Rolli FR, et al. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology 2017;66(6): 1814-25. https://doi.org/10.1002/hep.29399
  12. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology 2018; 154(6):1706-18.e1. https://doi.org/10.1053/j.gastro.2018.01.064
  13. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68(1):78-88. https://doi.org/10.1002/hep.29594
  14. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69(4):1599-613. https://doi.org/10.1002/hep.30330
  15. Kim YA, Lee YR, Park J, et al. Socioeconomic burden of cancer in Korea from 2011 to 2015. Cancer Res Treat 2020;52(3):896-906. https://doi.org/10.4143/crt.2019.398
  16. Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 2014;36:e2014008.
  17. Kim DW, Lee SM, Lim HS, et al. A Study on the operational definition of disease based on national health insurance claim data. 2017 NHIS Ilsan hospital institute health insurance & clinical research. 2017 Dec. 88p. Report No.: 2017-20-029.
  18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-83. https://doi.org/10.1016/0021-9681(87)90171-8
  19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130-9. https://doi.org/10.1097/01.mlr.0000182534.19832.83
  20. Kim J, Hahm MI, Park EC, et al. Economic burden of cancer in South Korea for the year 2005. J Prev Med Public Health 2009;42(3):190-8. https://doi.org/10.3961/jpmph.2009.42.3.190
  21. Kim JH. 2018 Korean Liver Cancer Association and National Cancer Center for Clinical Practice Guidelines of Hepatocellular Carcinoma: What's Different from 2014? Korean J Gastroenterol 2019;74(2):101-9. https://doi.org/10.4166/kjg.2019.74.2.101
  22. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50(1):89-99. https://doi.org/10.1016/j.jhep.2008.07.029
  23. White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 2012; 10(5):547-54. https://doi.org/10.1016/j.cgh.2011.12.031
  24. Nguang SH, Wu CK, Liang CM, et al. Treatment and cost of hepatocellular carcinoma: A population-based cohort study in Taiwan. Int J Environ Res Public Health 2018;15(12):2655. https://doi.org/10.3390/ijerph15122655
  25. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35(9):2155-66. https://doi.org/10.1111/liv.12818
  26. Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014;37(2): 438-44. https://doi.org/10.1007/s00270-013-0656-5
  27. Hong YM, Yoon KT, Cho M, et al. Trends and patterns of hepatocellular carcinoma treatment in Korea. J Korean Med Sci 2016;31(3):403-9. https://doi.org/10.3346/jkms.2016.31.3.403
  28. Kwon JW, Shin S, Lee JH, et al. The Impact of the national Liver Cancer Surveillnace Program on the Early Detection, Mortality and Medical cost. National Evidence-based Healthcare Collaboraing Agency 2016. Available from https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=234. Accessed March 21, 2021.
  29. Kim Y, Shin S, Park J, et al. Costing methods in Healthcare. Available from https://www.neca.re.kr/lay1/bbs/S1T11C102/F/39/view.do?article_seq=5332&cpage=1&rows=10&condition=&keyword=&show=&cat. Accessed March 21, 2021.